Search Orphan Drug Designations and Approvals
-
| Generic Name: | a ligand binding moiety to STAT3, a chemical linker, and a ligand binding moiety to an E3 ligase that leads to STAT3 degradation |
|---|---|
| Date Designated: | 09/14/2022 |
| Orphan Designation: | Treatment of Cutaneous T-Cell Lymphoma (CTCL) |
| Orphan Designation Status: | Designated |
| FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
| Sponsor: |
Kymera Therapeutics 500 North Beacon St. Watertown, Massachusetts 02472 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-







